2023
The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.Peer-Reviewed Original Research
2022
PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?
Ghali F, Roudier M, Vakar-Lopez F, Garcia J, Wang Y, Ha G, Grivas P, Lee J, Yu E, Montgomery B, Hsieh A, Wright J, Lam H. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS? Journal Of Urology 2022, 207: e913. DOI: 10.1097/ju.0000000000002630.09.Peer-Reviewed Original Research
2021
MP42-17 ASSOCIATION OF TUMOR HISTOLOGY ON IMPACT OF LYMPH NODE DISSECTION ON SURVIVAL IN T2-T3 RENAL CELL CARCINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASE
Ghali F, Cedars B, Patel D, Javier-Desloges J, Meagher M, Yuan J, Hakimi K, Soliman S, Patel S, Ballon-Landa E, Murphy J, Derweesh I. MP42-17 ASSOCIATION OF TUMOR HISTOLOGY ON IMPACT OF LYMPH NODE DISSECTION ON SURVIVAL IN T2-T3 RENAL CELL CARCINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASE. Journal Of Urology 2021, 206: e778-e779. DOI: 10.1097/ju.0000000000002063.17.Peer-Reviewed Original Research
2020
840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry
Campi R, Marchioni M, Roussel E, Capitanio U, Klatte T, Kriegmair M, Erdem S, Rubio-Briones J, Minervini A, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Autorino R, Pavan N, Antonelli A, Palumbo C, Guruli G, Ghali F, Amiel T, Mir M, Group Y. 840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry. European Urology Open Science 2020, 19: e1274-e1275. DOI: 10.1016/s2666-1683(20)33438-8.Peer-Reviewed Original Research846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry
Meagher M, Mir M, Rubio J, Campi R, Minervini A, Kriegmair M, Heck M, Van Bruwaene S, Linares E, Hevia V, Musquera M, D’anna M, Ghali F, Patel D, Bradshaw A, Autorino R, Guruli G, Rousel E, Albertsen M, Pavan N, Claps F, Antonelli A, Palumbo C, Marchioni M, Derweesh I. 846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry. European Urology Open Science 2020, 19: e1285-e1286. DOI: 10.1016/s2666-1683(20)33444-3.Peer-Reviewed Original Research